Our tests have been clinically validated, peer reviewed and included in major medical guidelines, proving the significance of our science for physicians and patients.
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S.
J Natl Cancer Inst. 2013 May 15;105(10):701-10.
A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.
Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Tuck A, Sengupta S, Elavathil L, Jani PA, Bonin M, Chang MC, Robertson SJ, Slodkowska E, Fong C, Anderson JM, Jamshidian F, Miller DP, Cherbavaz DB, Shak S, Paszat L.
Breast Cancer Res Treat. 2015 Jul;152(2):389-98.
Numerous studies from around the world consistently demonstrate that Oncotype DX changes physician treatment recommendations 30-40% of the time, underscoring its significant impact in clinical practice.
Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.
Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB, Frazier TG, Li L, Leonard CE, Carter DL, Chawla S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, Wapnir IL, Horst KC, Chagpar A, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, Hwang ES, White J.
Ann Surg Oncol. 2016 Oct 4. [Epub ahead of print]